Patents by Inventor Rachel S Welt

Rachel S Welt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies targeting B-cell receptor complex membrane bound IgM and uses thereof
    Patent number: 10227419
    Abstract: The present invention relates to antibodies targeting the membrane bound IgM (mIgM) of the B-cell receptor complex found in B-cell lymphomas and leukemias and uses thereof. Another aspect of the present invention is the use of anti-B-Cell mIgM antibodies in the treatment of Be-cell malignancies, including B-cell lymphomas and leukemias.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: March 12, 2019
    Assignee: Welt Bio-Molecular Pharmaceutical, LLC.
    Inventors: Sydney Welt, David Kostyal, Rachel S Welt, Virginia Raymond, Jonathan A Welt
  • ANTIBODIES TARGETING B-CELL RECEPTOR COMPLEX MEMBRANE BOUND IGM AND USES THEREOF
    Publication number: 20180186895
    Abstract: The present invention relates to antibodies targeting the membrane bound IgM (mIgM) of the B-cell receptor complex found in B-cell lymphomas and leukemias and uses thereof. Another aspect of the present invention is the use of anti-B-Cell mIgM antibodies in the treatment of Be-cell malignancies, including B-cell lymphomas and leukemias.
    Type: Application
    Filed: February 13, 2018
    Publication date: July 5, 2018
    Inventors: Sydney Welt, David Kostyal, Rachel S. Welt, Virginia Raymond, Jonathan A. Welt
  • Antibodies targeting B-cell receptor complex membrane bound IGM and uses thereof
    Patent number: 9926381
    Abstract: The present invention relates to monoclonal antibodies targeting the membrane bound IgM (mIgM) of the B-cell receptor complex found in B-cell lymphomas and leukemias. Monoclonal antibodies designated mAb4-2b, mAb1-1, mAb2-2b and mAb3-2b were produced by hybridoma cell lines (ATCC deposit no. PTA-121716), (ATCC deposit no. PTA-121719), (ATCC deposit no. PTA-121717), and (ATCC deposit no. PTA-121718), respectively. Another aspect of the present invention is the use of anti-B-Cell mIgM antibodies in the treatment of B-cell malignancies, including B-cell lymphomas and leukemias.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: March 27, 2018
    Assignee: WELT BIO-MOLECULAR PHARMACEUTICAL, LLC.
    Inventors: Sydney Welt, David Kostyal, Rachel S Welt, Virginia Raymond, Jonathan A Welt
  • ANTIBODIES TARGETING B-CELL RECEPTOR COMPLEX MEMBRANE BOUND IGM AND USES THEREOF
    Publication number: 20160304625
    Abstract: The present invention relates to antibodies targeting the membrane bound IgM (mIgM) of the B-cell receptor complex found in B-cell lymphomas and leukemias and uses thereof. Another aspect of the present invention is the use of anti-B-Cell mIgM antibodies in the treatment of Be-cell malignancies, including B-cell lymphomas and leukemias.
    Type: Application
    Filed: December 1, 2014
    Publication date: October 20, 2016
    Inventors: Sydney Welt, David Kostyal, Rachel S Welt, Virginia Raymond, Jonathan A Welt